Jefferies London 2026: Zealand Pharma CEO Adam Steensberg gives an update on the company's amylin program and comments on recent data from its Boehringer partnered glucagon/GLP-1

From BiotechTV - News · 00:14:11

Show by BiotechTV

He shares his strong belief that for most people taking obesity medicines going forward, tolerability could be the most important factor of choice, which is amylin's strong suit.

More episodes of BiotechTV - News

More episodes

PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.